{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:16:39Z","timestamp":1788225399661,"version":"build-2803163510"},"reference-count":42,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2026,7,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Tuberculosis (TB) remains a global health threat, with multidrug-resistant TB (MDR-TB) presenting major therapeutic challenges. Fluoroquinolones (FQs) are key second-line drugs. Resistance is typically linked to mutations within quinolone resistance-determining regions (QRDRs), though non-canonical mechanisms are increasingly recognized. To evaluate phenotypic susceptibility to gemifloxacin in clinical\n                      <jats:italic toggle=\"yes\">Mycobacterium tuberculosis<\/jats:italic>\n                      isolates and determine the association with mutations in\n                      <jats:italic toggle=\"yes\">gyrA<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">gyrB<\/jats:italic>\n                      QRDRs. Sixty clinical isolates (40 drug-susceptible [DS], 20 MDR) were tested using the resazurin microtiter assay (REMA). Minimum inhibitory concentrations (MICs) ranged from 0.25 to 128 \u00b5g\/mL. Resistance was defined using an epidemiological cutoff value (ECOFF) of \u22658 \u00b5g\/mL. Sanger sequencing of QRDR hotspots in gyrA (codons 90, 91, 94) and gyrB (codons 500\u2013540) was performed on all six resistant isolates and two susceptible controls. MDR isolates exhibited significantly higher median MICs compared to DS isolates (4 \u00b5g\/mL vs 2 \u00b5g\/mL,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.04). Six isolates (10%) were phenotypically resistant, including two DS and four MDR strains. Given our modest sample size (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 60), no mutations were detected within the sequenced QRDR segments of\n                      <jats:italic toggle=\"yes\">gyrA<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">gyrB<\/jats:italic>\n                      in any resistant isolate or control. In this hypothesis-generating study, gemifloxacin resistance was observed in\n                      <jats:italic toggle=\"yes\">M. tuberculosis<\/jats:italic>\n                      without mutations in the sequenced QRDR regions of\n                      <jats:italic toggle=\"yes\">gyrA<\/jats:italic>\n                      \/\n                      <jats:italic toggle=\"yes\">gyrB<\/jats:italic>\n                      , implying alternative mechanisms, such as efflux pump activity or altered permeability. While limited by sample size, these preliminary findings challenge the reliance on molecular diagnostics targeting only QRDRs and underscore the importance of phenotypic testing for accurate detection of resistance. Larger multicenter studies are warranted to validate these observations and elucidate the underlying mechanisms.\n                    <\/jats:p>\n                    <jats:sec>\n                      <jats:title>IMPORTANCE<\/jats:title>\n                      <jats:p>\n                        This study provides the first evidence that\n                        <jats:italic toggle=\"yes\">Mycobacterium tuberculosis<\/jats:italic>\n                        can develop phenotypic resistance to gemifloxacin\u2014despite having no mutations in the canonical gyrA\/gyrB quinolone resistance-determining regions (QRDRs). Among 60 clinical isolates, 10% of gemifloxacin-resistant strains were QRDR-negative. Although gemifloxacin is no longer used clinically due to toxicity, its unique structure reveals hidden, non-target-based resistance mechanisms (e.g., efflux, permeability changes) that likely also compromise current fluoroquinolones like levofloxacin and moxifloxacin. This exposes a critical blind spot: current molecular diagnostics (e.g., Xpert MTB\/XDR, GenoType) may falsely label resistant strains as susceptible, risking treatment failure. We argue that phenotypic drug susceptibility testing (DST) must be mandatory\u2014not optional\u2014in multidrug-resistant tuberculosis (MDR-TB) programs to safeguard against this silent, undetected resistance.\n                      <\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1128\/spectrum.03710-25","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:01:02Z","timestamp":1781524862000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Gemifloxacin resistance in\n                    <i>Mycobacterium tuberculosis<\/i>\n                    without QRDR mutations in\n                    <i>gyrA<\/i>\n                    or\n                    <i>gyrB<\/i>\n                    : evidence for non-canonical resistance mechanisms"],"prefix":"10.1128","volume":"14","author":[{"given":"Niloofar","family":"Hekmatpour","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01kzn7k21","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Microbiology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University","place":["Tehran, Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Hajizadeh","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01kzn7k21","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Microbiology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University","place":["Tehran, Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Yousefi","sequence":"additional","affiliation":[{"name":"Advanced-Sciences and Technology Faculty, Islamic Azad University, Tehran Medical Branch","place":["Tehran, Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Marjani","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/034m2b326","id-type":"ROR","asserted-by":"publisher"}],"name":"Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences","place":["Tehran, Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7141-322X","authenticated-orcid":true,"given":"Samira","family":"Tarashi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00wqczk30","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran","place":["Tehran, Iran"]},{"id":[{"id":"https:\/\/ror.org\/00wqczk30","id-type":"ROR","asserted-by":"publisher"}],"name":"Microbiology Research Center (MRC), Pasteur Institute of Iran","place":["Tehran, Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6892-5603","authenticated-orcid":true,"given":"Seyed Davar","family":"Siadat","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00wqczk30","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran","place":["Tehran, Iran"]},{"id":[{"id":"https:\/\/ror.org\/00wqczk30","id-type":"ROR","asserted-by":"publisher"}],"name":"Microbiology Research Center (MRC), Pasteur Institute of Iran","place":["Tehran, Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"Organization WH. 2025. Governance for public health across the health and allied sectors: a report to guide country-level institutional capacity for essential public health functions underpinning multisectoral approaches. World Health Organization"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7312a4"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2024.01.010"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00504-2"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2025.107849"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.001825"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020371"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2025.102766"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120470"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-87516-0"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00284-022-03021-1"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e07566"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02202-12"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-15955-8_47"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/9781555817817"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28041762"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.2174\/1570193X19666211221150119"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2013.28.3.378"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K347"},{"key":"e_1_3_3_21_2","volume-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update","author":"Organization WH","year":"2022","unstructured":"Organization WH. 2022. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. World Health Organization."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp174"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2019.06.008"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-90089-x"},{"key":"e_1_3_3_25_2","first-page":"21","article-title":"Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes","volume":"41","author":"Canetti G","year":"1969","unstructured":"Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, Mitchison DA, Rist N, Smelev NA. 1969. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 41:21\u201343.","journal-title":"Bull World Health Organ"},{"key":"e_1_3_3_26_2","unstructured":"Organization WH. 2018. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.5772\/34309"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.3791\/67672"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.5897\/AJMR10.278"},{"key":"e_1_3_3_30_2","first-page":"404","article-title":"Evaluation of drug susceptibility to rifampicin, INH and linezolid using resazurine microtitre assay","volume":"4","author":"Patidar V","year":"2015","unstructured":"Patidar V, Hemvani N, Chitnis D. 2015. Evaluation of drug susceptibility to rifampicin, INH and linezolid using resazurine microtitre assay. Int J Curr Microbiol Appl Sci 4:404\u2013412.","journal-title":"Int J Curr Microbiol Appl Sci"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-57992-x"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01623-23"},{"key":"e_1_3_3_33_2","unstructured":"Testing ECoAS. 2022. EUCAST. The European Committee on Antimicrobial Susceptibility Testing"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-S3-O14"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-020-1172-4"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","unstructured":"Rai SK Singh DB Singh S. 2025. Deciphering the electrostatic and structural dynamics due to point mutation in DNA gyrase leading to acquired quinolone resistance in Mycobacterium tuberculosis. Res Sq. doi:10.21203\/rs.3.rs-5778481\/v1","DOI":"10.21203\/rs.3.rs-5778481\/v1"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.05286-11"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-020-05112-5"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01663-20"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.10.2703-2709.2001"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9020255"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01983-21"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.29196\/jubpas.v30i4.4521"}],"container-title":["Microbiology Spectrum"],"original-title":[],"contributor":[{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"reviewer"}]}],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.03710-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.03710-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:02:12Z","timestamp":1788224532000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.03710-25"}},"subtitle":[],"editor":[{"given":"Florence Claude","family":"Doucet-Populaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,7]]}},"alternative-id":["10.1128\/spectrum.03710-25"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.03710-25","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"2025-12-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e03710-25"}}